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Background: The current healthcare climate demands pharmacoeconomic evaluations for different treatment
strategies incorporating drug acquisition costs, costs incurred for hospitalisation, drug administration and preparation,
diagnostic and laboratory testing and drug-related adverse events (AEs). Here we evaluate the pharmacoeconomics
of voriconazole versus liposomal amphotericin B as first-line therapies for invasive aspergillosis (IA) in patients with
haematological malignancy and prolonged neutropenia or who were undergoing haematopoietic stem-cell
transplantation in Germany or Spain.
Methods: A decision analytic model based on a decision tree was constructed to estimate the potential treatment
costs of voriconazole versus liposomal amphotericin B. Each model pathway was defined by the probability of an
event occurring and the costs of clinical outcomes. Outcome probabilities and cost inputs were derived from the
published literature, clinical trials, expert panels and local database costs. In the base case, patients who failed to
respond to first-line therapy were assumed to experience a single switch between comparator drugs or the other
drug was added as second-line treatment. Base-case evaluation included only drug-management costs and additional
hospitalisation costs due to severe AEs associated with first- and second-line therapies. Sensitivity analyses were
conducted to assess the robustness of the results. Cost estimates were inflated to 2011 euros (€).
Results: Based on clinical trial success rates of 52.8% (voriconazole) and 50.0% (liposomal amphotericin B), voriconazole
had lower total treatment costs compared with liposomal amphotericin B in both Germany (€12,256 versus €18,133;
length of therapy [LOT] = 10-day intravenous [IV] + 5-day oral voriconazole and 15-day IV liposomal amphotericin B)
and Spain (€8,032 versus €10,516; LOT = 7-day IV + 8-day oral voriconazole and 15-day IV liposomal amphotericin B).
Assuming the same efficacy (50.0%) in first-line therapy, voriconazole maintained a lower total treatment cost
compared with liposomal amphotericin B. Cost savings were primarily due to the lower drug acquisition costs and
shorter IV LOT associated with voriconazole. Sensitivity analyses showed that the results were sensitive to drug price,
particularly the cost of liposomal amphotericin B.
Conclusions: Voriconazole is likely to be cost-saving compared with liposomal amphotericin B when used as a
first-line treatment for IA in Germany and Spain.
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Invasive fungal diseases (IFDs) are a significant cause
of morbidity and mortality in immunocompromised
patients, and are associated with increased healthcare costs
[1]. The frequency of IFDs has increased substantially
over recent years, largely due to the increasing size of the
population at risk, which includes transplant recipients,
patients with haematological malignancies, and patients
with HIV [2].
Invasive aspergillosis (IA) is the most significant IFD
in immunocompromised patients, with an incidence
rate of approximately 10% in allogeneic bone marrow
transplant recipients [3], and an overall case-fatality
rate of 58% (range 43–87% depending on underlying
disease) [4]. As a result, patients with IA have a significantly
increased length of stay (LOS) in hospital and increased
healthcare costs compared with patients without IA [5-8].
The direct costs associated with IA are substantial and in-
clude inpatient and outpatient costs, such as increased LOS
in hospital, costs of antifungal therapy, and costs related to
the treatment of drug-related adverse events (AEs) [9].
Effective treatment of IFD is an ongoing challenge to
the clinical community from both a clinical and cost
perspective. Across Europe, treatment recommendations
are managed at a national level and are based on a range of
factors including: clinical outcomes (e.g. infection resolution
and mortality), economic outcomes (e.g. treatment costs
and hospital LOS) and quality of life information. In
Germany, the Infectious Diseases Working Party of
the German Society of Haematology and Oncology
provides guidelines for the diagnosis [10] and treatment
[11] of IFD in patients with haemato-oncological disorders.
In Spain, the Third European Conference on Infections
and Leukaemia [12] and the Spanish Society of Infectious
Diseases and Clinical Microbiology [13] provide specific
therapies and disease-management strategies.
Voriconazole (Vfend®, Pfizer Inc) and liposomal ampho-
tericin B (Ambisome®, Gilead Sciences) are licensed for
the treatment of IFD, including IA. In a prospective,
randomised trial of voriconazole versus amphotericin B
deoxycholate for the primary treatment of IA, voriconazole
demonstrated superior efficacy and improved survival,
and resulted in fewer side effects, compared with
amphotericin B [14].
Health economic-based models are designed to address
questions of economic relevance, and integrate efficacy and
safety data from clinical trials with medical resource use
and quality of life information from the published literature,
expert opinion and database analysis. Here, we evaluate
the pharmacoeconomics of voriconazole versus liposomal
amphotericin B as first-line therapies for IA in patients with
haematological malignancy and prolonged neutropenia, or
those undergoing haematopoietic stem cell transplantation
(HSCT), from German and Spanish hospital perspectives.Methods
Study design
This analysis was conducted from German and Spanish
hospital perspectives. The study population comprised
patients with haematological malignancy and prolonged
neutropenia or those undergoing HSCT. Eligible patients
met the criteria for proven or probable IA defined in the
key randomised clinical trials of voriconazole [14] and
liposomal amphotericin B [15]. Briefly, the key voriconazole
trial enrolled immunocompromised patients aged ≥12 years
with definite or probable IA. Patients were excluded if
they had chronic aspergillosis, aspergilloma or allergic
bronchopulmonary aspergillosis [14]. The key liposomal
amphotericin B trial enrolled patients who met the criteria
for proven or probable invasive mould infections as estab-
lished by the European Organisation for Research and
Treatment of Cancer/Mycosis Study Group; in addition, a
protocol-defined modification allowed a diagnosis of prob-
able IA in patients with a halo or air crescent sign on chest
computed tomography scan who had undergone allogeneic
stem cell transplantation or who had neutropenia within
14 days of study entry [15].
To estimate the potential therapy costs of voriconazole
versus liposomal amphotericin B, a decision analytic
model based on a decision tree was developed (Figure 1).
Each pathway in the model was defined by the probability
of an event occurring and the costs associated with each
clinical outcome defined as: (1) treatment success or (2)
treatment failure, which included add-on treatment due to
lack of response, switching to second-line therapy due to
serious AEs or for other reasons, and mortality.
The model inputs were treatment options, length of
therapy (LOT), additional LOS in hospital, other efficacy
and safety inputs, and drug costs. Outcome measures
were the total hospital costs (e.g. drug and hospitalisation
costs) associated with each therapy in 2011 euros (€).
Outcome probabilities and cost inputs were derived
from the published literature, clinical trials, expert panel
discussions and local database costs.
Key model assumptions
The model time horizon was the 30-day inpatient
follow-up period based on the mean LOS for HSCT pa-
tients with IA and haematological malignancy in a United
States claims database analysis [16].
In the base-case scenario, patients who failed to respond
to first-line therapy were assumed to undergo a single
switch between comparator drugs or the other drug was
added as a second-line therapy. Drug dosages were based
on patients having an average weight of 70 kg, as defined
in the key randomised clinical trials of voriconazole [14]
and liposomal amphotericin B [15]. Voriconazole was
administered intravenously at doses of 6 mg/kg twice daily











Add-on therapy due to lack of response
Switch to 2nd-line due to severe AEs 
Switch to 2nd-line due to other reasons 
Mortality
[+]
Initial therapy: 15 days
Base case: 30-day inpatient follow-up timeframe
~
Figure 1 Decision analytic model. AE, adverse event; BMT, bone marrow transplant; HSCT, haematopoietic stem-cell transplant; IA, invasive aspergillosis.
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tericin B was administered at a dose of 3 mg/kg once daily.
It was assumed that there was no vial wastage during use.
The first-line drugs, voriconazole and liposomal
amphotericin B, were only used in an inpatient setting
(mean LOS = 30 days). Second-line therapies could be
used in both inpatient and outpatient settings. IV LOT
was determined by clinical experts from each country.
In the German base-case scenario, first-line LOT was
10 days of IV voriconazole followed by 5 days of oral
voriconazole and 15 days of IV liposomal amphotericin
B. Second-line LOT was 15 days of IV voriconazole,
liposomal amphotericin B or caspofungin. In the
Spanish base-case scenario, first-line LOT was 7 days of
IV voriconazole followed by 8 days of oral voriconazole
and 15 days of IV liposomal amphotericin B. Second-line
LOT was 7 days of IV voriconazole followed by 8 days
of oral voriconazole and 15 days of IV liposomal
amphotericin B or caspofungin.
After the initial success of IV voriconazole, conversion
to oral voriconazole could be used as a first-line therapy,
and it could also be used as a second-line add-on or
switch-to therapy. If the comparator drug was added
as second-line combination therapy due to lack of
response with the first-line monotherapy, the first-line
drug (voriconazole or liposomal amphotericin B) was
continued as IV therapy (liposomal amphotericin B) or as
a combination of IV and oral therapy (voriconazole) for
the same duration as the add-on drug.
Cost calculation assumptions
The base-case evaluation included only drug-management
costs and additional hospitalisation costs due to severe
AEs associated with first- and second-line therapies.Based on the results of the key randomised clinical trials,
severe AEs with first- and second-line therapies included
nephrotoxicity and hypokalaemia [14,15]. Although the
effects of infusion-related reactions (e.g. visual disturbances,
chest pain and back pain) were reported to be significantly
different between the two treatment arms, it was assumed
that the impact of moderate/severe infusion-related reac-
tions would be captured by the pathway of treatment fail-
ure/switch due to AEs, and that additional costs incurred
due to mild infusion-related reactions were minimal.
Hospital LOS was not included in the cost calculation
as it was assumed to be similar across the different
therapies. Based on a previously published study that
assessed additional resource utilisation associated with
AEs, an additional 2.2 days of hospital stay was applied to
both treatment arms in the base-case scenario to reflect
the impact of severe AEs [17].Clinical input
Clinical efficacy, safety and mortality data in this model
were based on the default drug dosages and were obtained
from the key randomised clinical trials of voriconazole
[14] and liposomal amphotericin B [15] (Table 1). The
probability of adding another antifungal drug to the
regimen due to lack of response was calculated as 1
minus the switch rate to second-line therapy.Costs of medical resource and drug acquisition
Hospitalisation costs and outpatient IV administration
costs were based on economic research on the treatment
of IA in Germany [1,18,19] and Spain [20] (Table 2).
Drug acquisition costs in Germany were derived from
the LAUER-Taxe, Pharmindex for Germany drug costs
Table 3 Drug acquisition costs (2011 €)
Unit price
(per vial or tablet) (€)






due to severe AEs (%)
Switch





Voriconazole 52.8 19.2 13.4 9.0 13.4 5.6
Liposomal amphotericin B 50.0 8.7 20.0 16.0 20.0 5.3
Data sources: [14,15].
AE, adverse event.
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derived from the Bot Plus database (Table 3) [22].
Sensitivity analysis
The effects of individual parameters (e.g. drug price
and hospital costs) were examined by varying esti-
mates by ±30%. Sensitivity results for each input were
ranked from the most sensitive to the least sensitive
via a tornado diagram.
Results
German hospital perspective
Based on clinical trial success rates of 52.8% for vorico-
nazole and 50.0% for liposomal amphotericin B and a
LOT of 10 days for IV voriconazole followed by 5 days
for oral voriconazole and 15 days for IV liposomal
amphotericin B, voriconazole had a lower total treatment
cost compared with liposomal amphotericin B (€12,256
versus €18,133) (Figure 2A). If the same LOT of 10 days
was assumed for both arms (IV only), voriconazole
maintained a lower total treatment cost of €9,472
compared with the total treatment cost of €12,250 for
liposomal amphotericin B. If the same efficacy (50.0%)
was assumed for both first-line therapies, voriconazole
maintained a lower total treatment cost compared
with liposomal amphotericin B (€12,836 versus €18,133,
respectively, over 15 days of treatment, and €9,862
versus €12,250, respectively, over 10 days of treatment)
(Figure 3A).
When total treatment costs were broken down by line
of therapy, first-line therapy costs were substantially
lower for voriconazole versus liposomal amphotericin B,
whereas second-line therapy costs were lower for liposomal
amphotericin B versus voriconazole. These observations
remained consistent regardless of whether LOT was 10 or
15 days and whether efficacy assumptions were based on
clinical trial success rates or equivalency. AEs accounted for
3.9% (€199 of €5,094) and 2.1% (€297 of €13,816) of theTable 2 Inpatient and outpatient costs (2011 €)
Price (€)
Setting Description Germany Spain
Inpatient Hospitalisation cost per day 674.10 566.52
Outpatient Intravenous administration cost per unit 34.90 34.90
Data sources: [1,18-20].total costs of first-line treatment with voriconazole
and liposomal amphotericin B, respectively.
The cost savings associated with voriconazole were
primarily due to lower drug acquisition costs and a
shorter IV LOT combined with the use of a cheaper oral
formulation. AE savings accounted for 1.0% of the total
cost saving associated with first-line voriconazole versus
liposomal amphotericin B.
Spanish hospital perspective
Based on clinical trial success rates of 52.8% for vorico-
nazole and 50.0% for liposomal amphotericin B and a
LOT of 7 days for IV voriconazole followed by 8 days of
oral voriconazole and 15 days for IV liposomal ampho-
tericin B, voriconazole had a lower total treatment cost
compared with liposomal amphotericin B (€8,032 versus
€10,516) (Figure 2B). When the same efficacy of 50.0%
was assumed for both first-line therapies, voriconazole
maintained a lower total treatment cost compared
with liposomal amphotericin B (€8,425 versus €10,516,
respectively) (Figure 3B).
Similar to the German hospital perspective, when
total treatment costs were broken down by therapy
line, first-line therapy costs were substantially lower for
voriconazole versus liposomal amphotericin B, whereas
second-line therapy costs were lower for liposomal ampho-
tericin B versus voriconazole. AEs accounted for 4.9%
(€167 of €3,443) and 3.0% (€249 of €8,225) of the total costs
of first-line treatment with voriconazole and liposomal
amphotericin B, respectively.
Cost savings with voriconazole were primarily due
to lower drug acquisition costs and a shorter IV LOT
combined with the use of a cheaper oral formulation.Treatment Dosage Germany Spain
Voriconazole 200 mg IV 156.00 133.32
Oral tablet 200 mg 45.00 35.68
Liposomal amphotericin B 50 mg IV 220.47 130.06
Caspofungin 70 mg IV 793.24 570.81
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Figure 2 Cost comparison for base-case scenario in (A) Germany and (B) Spain.
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associated with first-line voriconazole versus liposomal
amphotericin B.
Sensitivity analyses
Sensitivity analyses showed that the results of the model
were sensitive to drug price, particularly the cost of liposo-
mal amphotericin B. In the German hospital scenario
(LOT = 15 days) a variation in drug price of ±30% resulted
in upper and lower bounds for the €5,878 total cost
saving of €8,561 and €3,194 for liposomal amphotericin B,
€5,070 and €6,685 for the IV formulation of voricona-
zole, and €5,746 and €6,009 for the oral formulationof voriconazole. Similarly, in the Spanish hospital scenario
(LOT= 15 days), a variation in drug price of ±30% resulted
in upper and lower bounds for the €2,483 total cost saving
of €4,066 and €900 for liposomal amphotericin B, €1,719
and €3,247 for the IV formulation of voriconazole, and
€2,393 and €2,573 for the oral formulation of voriconazole.
Discussion
Pharmacoeconomic analyses are increasingly important
in the clinical arena where decision-makers face growing
pressure to optimise value and quality of care. In addition,
pharmacoeconomic analyses can also provide information
to support clinical decision-making to promote the
Figure 3 Cost comparison assuming equal efficacy in (A) Germany and (B) Spain.
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Improvements in efficacy and reductions in hospital
LOS and costs associated with AEs are clearly also
desirable outcomes for patients and clinicians.
The pharmacoeconomic evaluation described in this
article applies to the treatment of IA infections in
patients with haematological disorders in Germany
and Spain. The findings from our model, together with
the previously reported results from a randomised
clinical trial [14], suggest that voriconazole is likely to becost-saving as first-line therapy compared with liposomal
amphotericin B, and is a better treatment option from a
clinical, safety and economic perspective. This observation
was consistent across all scenarios tested in this analysis.
To the best of our knowledge, this is the first analysis
to directly compare the pharmacoeconomic costs of vori-
conazole and liposomal amphotericin B for the treatment
of IA. Wingard and colleagues compared the resource use
and cost of treatment for voriconazole with conventional
amphotericin B for IA and found that using voriconazole
Ostermann et al. BMC Pharmacology and Toxicology 2014, 15:52 Page 7 of 8
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and similar treatment costs [23]. Surviving patients who
were treated with voriconazole spent fewer days in
intensive care and more days out of hospital than
those who received amphotericin B [23]. In addition,
decision-tree modelling has suggested that voriconazole is
cost-saving overall compared with conventional ampho-
tericin B in clinical trial populations in the United States,
Canada, Germany and the Netherlands [18,24-26].
Cost savings associated with voriconazole were thought
to be attributable to its lower drug acquisition costs and
shorter IV LOT due to the availability of an oral formula-
tion of voriconazole. In the German model, a reduction in
the IV LOT from 15 to 10 days had a great impact on the
total treatment cost for liposomal amphotericin B, redu-
cing the total cost by approximately one-third. In clinical
practice, the IV LOT for voriconazole is often shorter than
10 days, which could lead to even greater cost savings.
In addition to cost savings, the availability of an oral
formulation of voriconazole offers several other advantages,
including ease of delivery, reduced infection risk in
an already immunocompromised patient population,
and improved patient compliance.
The limitations of this study included the use of clinical
trial data that may not be representative of the general
population, the absence of head-to-head data comparing
voriconazole with liposomal amphotericin B, and the
assumption of 100% efficacy with second-line therapy.
However, this assumption was required to prevent
extrapolation of the time horizon beyond 30 days and was
considered acceptable by clinical experts as no large trials
evaluating efficacy data for second-line therapies have
been conducted in this patient population.
Several factors, including drug-drug interactions and AEs,
contribute to the long-term costs of IA. As voriconazole is
an inhibitor of CYP3A4 liver enzymes, its concurrent use
with other agents that are metabolized by the same system
may result in substantial drug-drug interactions (e.g., con-
comitant use with immunosuppressive transplant medica-
tions) [27-29]. Voriconazole has also been associated with
an increased risk of hepatotoxicity, with studies reporting
significant transaminase abnormalities in 12.4% of patients
[30]; however, most instances of drug-induced hepatotox-
icity are unpredictable and vary considerably depending on
the population, indication, formulation, and dosage [31,32].
Although liposomal amphotericin B has been shown to be
substantially less toxic than conventional amphotericin B,
particularly with respect to infusion-related reactions and
nephrotoxicity, its use is still limited by these AEs [33].
Furthermore, concurrent use of liposomal amphotericin B
with other nephrotoxic agents (e.g., cyclosporine, aminogly-
cosides, polymixins, tacrolimus and pentamidine) has
been shown to increase the potential for drug-induced
nephrotoxicity in some patients [34].Conclusions
This study showed that voriconazole is likely to be
cost-saving compared with liposomal amphotericin B
for the first-line treatment of IA infections in patients
with haematological disorders in Germany and Spain. These
conclusions are valid for countries with a comparable
healthcare system and comparable drug costs; however,
studies using observational real-world data are required to
confirm these findings.
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